Does the FDA warn about any HRT side effects

DISCLOSURE: Voshell's Pharmacy is a licensed compounding pharmacy that prepares and sells compounded medications by prescription. As a provider of competing products, our perspective may be influenced by our professional and commercial interests.

According to FDA.gov, hormone therapy products carry labeling that discloses both common and serious potential side effects. The warnings do not mean hormone therapy is inappropriate for everyone; they are intended to guide informed decision-making between patients and their prescribers.

Compounded medications are not reviewed by FDA for safety or effectiveness before dispensing and are prepared by a licensed pharmacist only in response to a valid prescription for an individual patient. This page primarily discusses commercially available hormone therapy products.

Common FDA‑listed side effects

• Breast tenderness: A feeling of fullness or soreness, similar to pre‑menstrual tenderness.
• Bloating or fluid retention: Mild swelling in the abdomen, hands, or feet.
• Nausea: Usually improves with food or switching the dose or formulation.
• Headaches: May occur as the body adjusts to hormones.
• Vaginal spotting or bleeding: Especially during the first few months of therapy.

Less common but important FDA warnings

• Blood clots: According to FDA-approved prescribing information, estrogen taken by mouth may slightly increase the risk of clots in the legs or lungs. Transdermal estrogen (patch, gel, spray) has a much lower clot risk.
• Stroke: According to FDA Drug Safety Communication, a small increase in stroke risk is noted mainly in older women who start hormone therapy after age 60.
• Heart attack: According to FDA.gov, risk is mainly associated with starting oral estrogen later in life. Starting near menopause is associated with lower risk, though a qualified prescriber should assess individual cardiovascular history.
• Breast cancer: According to FDA-approved prescribing information, a small increased risk has been noted when estrogen is combined with progestin for several years. Estrogen alone (for women without a uterus) does not carry this same pattern.
• Gallbladder disease: According to FDA.gov, oral estrogen may increase the chance of gallstones or gallbladder inflammation.

Why these warnings exist

According to the WHI, many of these risks were identified in older, large studies that used higher‑dose, oral hormones. Modern clinical practice often uses lower doses and transdermal estrogen, which may reduce many of these risks. According to NAMS, the warnings remain so every woman and clinician may make a fully informed choice based on individual circumstances.

What this means for you

• Formulation matters: According to ACOG, transdermal estrogen and micronized progesterone are associated with a different risk profile than oral formulations.
• Individual health history: A qualified prescriber should review age, cardiovascular history, and other factors before initiating therapy.
• Regular check‑ins with a qualified prescriber help ensure the dose and route stay appropriate over time.

These warnings highlight areas to monitor so that hormone therapy may be used with appropriate oversight. Decisions about whether hormone therapy is appropriate should be made with a qualified prescriber.